Current Opinion in Hematology最新文献

Platelets come together, in sweet harmony?!

IF 3.1 3区医学

Current Opinion in Hematology Pub Date : 2025-01-01 Epub Date: 2024-12-05 DOI: 10.1097/MOH.0000000000000844

Dianne E van der Wal

引用次数: 0

Platelets and circulating (tumor) cells: partners in promoting metastatic cancer. 血小板和循环（及肿瘤）细胞：促进癌症转移的伙伴。

IF 3.1 3区医学

Current Opinion in Hematology Pub Date : 2025-01-01 Epub Date: 2024-11-21 DOI: 10.1097/MOH.0000000000000852

Deepa Gautam, Emily M Clarke, Harvey G Roweth, Margaret R Smith, Elisabeth M Battinelli

{"title":"Platelets and circulating (tumor) cells: partners in promoting metastatic cancer.","authors":"Deepa Gautam, Emily M Clarke, Harvey G Roweth, Margaret R Smith, Elisabeth M Battinelli","doi":"10.1097/MOH.0000000000000852","DOIUrl":"10.1097/MOH.0000000000000852","url":null,"abstract":"Purpose of review: Despite being discovered decades ago, metastasis remains a formidable challenge in cancer treatment. During the intermediate phase of metastasis, tumor cells detach from primary tumor or metastatic sites and travel through the bloodstream and lymphatic system to distant tissues. These tumor cells in the circulation are known as circulating tumor cells (CTCs), and a higher number of CTCs has been linked to poor prognoses in various cancers. The blood is an inhospitable environment for any foreign cells, including CTCs, as they face numerous challenges, such as the shear stress within blood vessels and their interactions with blood and immune cells. However, the exact mechanisms by which CTCs survive the hostile conditions of the bloodstream remain enigmatic. Platelets have been studied for their interactions with tumor cells, promoting their survival, growth, and metastasis. This review explores the latest clinical methods for enumerating CTCs, recent findings on platelet-CTC crosstalk, and current research on antiplatelet therapy as a potential strategy to inhibit metastasis, offering new therapeutic insights.Recent findings: Laboratory and clinical data have provided insights into the role of platelets in promoting CTC survival, while clinical advancements in CTC enumeration offer improved prognostic tools.Summary: CTCs play a critical role in metastasis, and their interactions with platelets aid their survival in the hostile environment of the bloodstream. Understanding this crosstalk offers insights into potential therapeutic strategies, including antiplatelet therapy, to inhibit metastasis and improve cancer treatment outcomes.","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"52-60"},"PeriodicalIF":3.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142589968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of selective serotonin reuptake inhibitors on platelet functions: a literature review. 选择性血清素再摄取抑制剂对血小板功能的影响：文献综述。

IF 3.1 3区医学

Current Opinion in Hematology Pub Date : 2025-01-01 Epub Date: 2024-10-09 DOI: 10.1097/MOH.0000000000000847

Antoine Mokhtarian, Virginie Siguret, Georges Jourdi

{"title":"Effects of selective serotonin reuptake inhibitors on platelet functions: a literature review.","authors":"Antoine Mokhtarian, Virginie Siguret, Georges Jourdi","doi":"10.1097/MOH.0000000000000847","DOIUrl":"10.1097/MOH.0000000000000847","url":null,"abstract":"Purpose of review: Many epidemiological studies have evidenced an increased bleeding risk associated with selective serotonin reuptake inhibitors (SSRIs), yet the underlying mechanisms remain unclear. This review summarizes data on SSRIs' effects on platelet functions assessed with assays used in clinical practice and highlights the areas that deserve further investigation.Recent findings: Conflicting results of SSRI effects on platelet aggregation were observed irrespectively of the agonist used, the antidepressant drug or the study type. Alike, discrepant results were reported with flow-cytometry-based assays assessing either platelet surface glycoprotein levels, integrin activation, agonist-induced secretion of intraplatelet granule content or membrane anionic phospholipid exposure. Other tests may have detected a platelet function defect in SSRIs samples, however, results were largely inconsistent.Summary: Critical literature examination unveils very low certainty of evidence on potential SSRI effect on platelet functions. Findings are often inconsistent even when similar methods are used, most likely because of differences in study design, included patients (age, comorbid conditions), SSRIs' type and dose, uncontrolled confounding factors, and statistical analysis power. Further studies are needed to disentangle any intrinsic antiplatelet effect of SSRIs and the multiple confounding factors, mainly the depression control itself and the degree of platelet SERT inhibition.","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"22-33"},"PeriodicalIF":3.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142481401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Editorial introductions.

IF 3.1 3区医学

Current Opinion in Hematology Pub Date : 2025-01-01 Epub Date: 2024-12-05 DOI: 10.1097/MOH.0000000000000851

引用次数: 0

HCT in the widening spectrum of congenital immunodeficiencies. HCT 在不断扩大的先天性免疫缺陷中的应用。

IF 3.1 3区医学

Current Opinion in Hematology Pub Date : 2025-01-01 Epub Date: 2024-11-25 DOI: 10.1097/MOH.0000000000000849

Rafaella Muratori, Carmem Bonfim

{"title":"HCT in the widening spectrum of congenital immunodeficiencies.","authors":"Rafaella Muratori, Carmem Bonfim","doi":"10.1097/MOH.0000000000000849","DOIUrl":"10.1097/MOH.0000000000000849","url":null,"abstract":"Purpose of review: Hematopoietic stem cell transplantation (HSCT) and inborn errors of immunity (IEI) have been closely linked since transplantation was first used to cure severe combined immunodeficiency (SCID) in 1968. Since then, novel genes and diseases have been continually added to the ongoing list of IEI, and new data on indications and outcomes have emerged. We review recent data and progress in the field of hematopoietic cell transplantation (HCT) for IEI including new diseases and complications.Recent findings: Emerging data from haploidentical transplants, newborn screening results, and multicentric studies reveals promising outcomes for IEI. Immune dysregulation diseases deserve special attention regarding disease control and may require additional drugs pretransplant. Female carriers of X-linked Chronic granulomatous may present with a severe phenotype warranting the need for HCT. Insights from infectious complications and long-term comorbidities should help guide decisions to treat IEI patients.Summary: From classical indications to recently described diseases, HCT for immunodeficiencies is a rapidly growing field. Novel data regarding alternative donor transplants, results from large cohorts, and long-term complications provide valuable knowledge for clinical practice.","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"61-66"},"PeriodicalIF":3.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142734855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Platelet transfusion. 血小板输注。

IF 3.1 3区医学

Current Opinion in Hematology Pub Date : 2025-01-01 Epub Date: 2024-09-05 DOI: 10.1097/MOH.0000000000000843

Allison Mo, Erica Wood, Zoe McQuilten

{"title":"Platelet transfusion.","authors":"Allison Mo, Erica Wood, Zoe McQuilten","doi":"10.1097/MOH.0000000000000843","DOIUrl":"10.1097/MOH.0000000000000843","url":null,"abstract":"Purpose of review: Platelet transfusions, used as prophylaxis or treatment for bleeding, are potentially life-saving. In many countries, demand for platelet transfusion is rising. Platelets are a limited and costly resource, and it is vital that they are used appropriately. This study will explore the evidence behind platelet transfusions in different contexts, in particular recent and important research in this area.Recent findings: Recent randomized clinical trials demonstrate the efficacy of platelet transfusions in some contexts but potential detrimental effects in others. Platelet transfusions also carry risk of transfusion reactions, bacterial contamination and platelet transfusion refractoriness. Observational and clinical studies, which highlight approaches to mitigate these risks, will be discussed. There is growing interest in cold-stored or cryopreserved platelet units, which may improve platelet function and availability. Clinical trials also highlight the efficacy of other supportive measures such as tranexamic acid or thrombopoietin receptor agonists in patients with bleeding.Summary: Although platelet transfusions are beneficial in many patients, there remain many settings in which the optimal use of platelet transfusions is unclear, and some situations in which they may have detrimental effects. Future clinical trials are needed to determine optimal use of platelet transfusions in different patient populations.","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"14-21"},"PeriodicalIF":3.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142301432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Platelet-derived extracellular vesicles in cardiovascular disease and treatment - from maintaining homeostasis to targeted drug delivery. 心血管疾病和治疗中的血小板源性细胞外囊泡--从维持体内平衡到靶向给药。

IF 3.1 3区医学

Current Opinion in Hematology Pub Date : 2025-01-01 Epub Date: 2024-10-08 DOI: 10.1097/MOH.0000000000000845

Luisa Weiss, Hayley Macleod, Patricia B Maguire

{"title":"Platelet-derived extracellular vesicles in cardiovascular disease and treatment - from maintaining homeostasis to targeted drug delivery.","authors":"Luisa Weiss, Hayley Macleod, Patricia B Maguire","doi":"10.1097/MOH.0000000000000845","DOIUrl":"10.1097/MOH.0000000000000845","url":null,"abstract":"Purpose of review: Cardiovascular disease (CVD) remains a major global health burden. Rising incidences necessitate improved understanding of the pathophysiological processes underlying disease progression to foster the development of novel therapeutic strategies. Besides their well recognized role in CVD, platelet-derived extracellular vesicles (PEVs) mediate inter-organ cross talk and contribute to various inflammatory diseases.Recent findings: PEVs are readily accessible diagnostic biomarkers that mirror pathophysiological disease progression but also may confer cardioprotective properties. Monitoring the effects of modulation of PEV signatures through pharmacotherapies has also provided novel insights into treatment efficacy. Furthermore, exploiting their inherent ability to infiltrate thrombi, atherosclerotic plaques and solid tumours, PEVs as well as platelet-membrane coated nanoparticles are emerging as novel effective and targeted treatment options for CVD and cancer.Summary: Collectively, in-depth characterization of PEVs in various diseases ultimately enhances their use as diagnostic or prognostic biomarkers and potential therapeutic targets, making them clinically relevant candidates to positively impact patient outcomes.","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"4-13"},"PeriodicalIF":3.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11620325/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142395462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Desialylation by neuraminidases in platelets, kiss of death or bittersweet? 血小板中神经氨酸酶的去酰化作用，死亡之吻还是苦乐参半？

IF 3.1 3区医学

Current Opinion in Hematology Pub Date : 2025-01-01 Epub Date: 2024-08-30 DOI: 10.1097/MOH.0000000000000815

Nora Butta, Dianne E van der Wal

引用次数: 0

PROTACs in platelets: emerging antithrombotic strategies and future perspectives. 血小板中的 PROTACs：新出现的抗血栓策略和未来展望。

IF 3.1 3区医学

Current Opinion in Hematology Pub Date : 2025-01-01 Epub Date: 2024-10-18 DOI: 10.1097/MOH.0000000000000846

Justin S Trory, Jordan Vautrinot, Carl J May, Ingeborg Hers

{"title":"PROTACs in platelets: emerging antithrombotic strategies and future perspectives.","authors":"Justin S Trory, Jordan Vautrinot, Carl J May, Ingeborg Hers","doi":"10.1097/MOH.0000000000000846","DOIUrl":"10.1097/MOH.0000000000000846","url":null,"abstract":"Purpose of review: Proteolysis-targeted chimeras (PROTACs) are heterobifunctional compounds that selectively target proteins for degradation and are an emerging therapeutic modality to treat diseases such as cancer and neurodegenerative disorders. This review will widen the area of application by highlighting the ability of PROTACs to remove proteins from the anucleate platelets and evaluate their antithrombotic potential.Recent findings: Proteomic and biochemical studies demonstrated that human platelets possess the Ubiquitin Proteasomal System as well as the E3 ligase cereblon (CRBN) and therefore may be susceptible to PROTAC-mediated protein degradation. Recent findings confirmed that CRBN ligand-based PROTACs targeting generic tyrosine kinases, Btk and/or Fak lead to efficacious and selective protein degradation in human platelets. Downregulation of Btk, a key player involved in signalling to thrombosis, but not haemostasis, resulted in impaired in-vitro thrombus formation.Summary: Platelets are susceptible to targeted protein degradation by CRBN ligand-based PROTACs and have limited ability to resynthesise proteins, ensuring long-term downregulation of target proteins. Therefore, PROTACs serve as an additional research tool to study platelet function and offer new therapeutic potential to prevent thrombosis. Future studies should focus on enhancing cell specificity to avoid on-target side effects on other blood cells.","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"34-42"},"PeriodicalIF":3.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142513344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Models to study myelodysplastic syndrome and acute myeloid leukaemia. 研究骨髓增生异常综合症和急性髓性白血病的模型。

IF 3.1 3区医学

Current Opinion in Hematology Pub Date : 2024-11-28 DOI: 10.1097/MOH.0000000000000856

Clifford Chao, Isabella G Martinez, Elvin Wagenblast

{"title":"Models to study myelodysplastic syndrome and acute myeloid leukaemia.","authors":"Clifford Chao, Isabella G Martinez, Elvin Wagenblast","doi":"10.1097/MOH.0000000000000856","DOIUrl":"https://doi.org/10.1097/MOH.0000000000000856","url":null,"abstract":"Purpose of review: Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematological malignancies characterized by complex genetic alterations, leading to poor clinical outcomes. Despite advances in treatment, there is an urgent need for novel therapeutic approaches. This review outlines recent progress in humanized models of MDS and AML and highlight their role in advancing our understanding of these diseases.Recent findings: Patient derived xenografts (PDXs) were among the first humanized models for studying MDS and AML, allowing researchers to analyze patient-specific cancer properties in vivo. However, they face challenges related to sample availability and consistent engraftment in mice. New methods, including specialized mouse strains and human tissue scaffolds, have been developed to address these issues. Induced pluripotent stem cells (iPSCs) offer the advantage of indefinite expansion and genetic modification, making them valuable for in vitro research, though protocols to enhance their engraftment in vivo are still being refined. Genetically engineered human primary hematopoietic stem and progenitor cells (HSPCs) provide reliable in vivo models with good engraftment in mice, and recent advancements in culture systems and gene-editing techniques are helping to overcome challenges related to ex vivo expansion and genetic modification.Summary: PDXs, iPSCs, and genetically engineered HSPCs are crucial models for the study of MDS and AML. This review discusses strengths, limitations, and recent advancements of these humanized models, which provide insights into human-specific disease biology and therapeutic development.","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142741502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0